Latest / CME Outfitters Medical Education / Riding the Waves of Obesity Science – Reaching the Shoreline: Emerging Amylin-Based Therapies and Trial Signals
Transcript
- 0:10SPEAKER_01: Hello, I'm Dr.
- 0:11SPEAKER_01: Robert Christianer.
- 0:12SPEAKER_01: I'd like to welcome you to Riding the Waves of Obesity Science.
- 0:17SPEAKER_01: This is the final activity of our Four Snack series and is titled Reaching the Shoreline: Emerging Amlin-Based Therapies and Trial Signals.
- 0:27SPEAKER_01: This activity is provided by CME Outfitters and is supported by an independent educational grant from Novo Nordisk, Incorporated.
- 0:36SPEAKER_01: After participating in today's activities, learners should be able to assess emerging amlin-based therapeutic strategies and obesity management and differentiate key trial signals that inform interpretation of investigational data.
- 0:53SPEAKER_01: Again, I'm Dr.
- 0:53SPEAKER_01: Robert Krishner.
- 0:54SPEAKER_01: I'm Professor Emeritus at Northwestern University Feinberg School of Medicine in the Departments of Medicine and Medical Education.
- 1:02SPEAKER_01: And I'm very pleased to welcome Dr.
- 1:04SPEAKER_01: Timothy Garvey, whom I will ask to introduce himself.
- 1:08SPEAKER_01: Welcome, Dr.
- 1:09SPEAKER_01: Garvey.
- 1:10SPEAKER_00: Thank you, Bob.
- 1:11SPEAKER_00: Yes, my name is Tim Garvey.
- 1:13SPEAKER_00: I'm an endocrinologist, a professor at the University of Alabama at Birmingham.
- 1:18SPEAKER_00: I've uh I do plenty of clinical trials in patients with obesity and diabetes, and really have been at this uh for quite a number of years.
- 1:27SPEAKER_01: Tim, you know, I can't think of a better person to close this series out.
- 1:32SPEAKER_01: You're an expert in the field, you are a principal investigator, and you've written so much about this topic.
- 1:39SPEAKER_01: And uh really it's up to you to bring it to a close.
- 1:42SPEAKER_01: So to remind our listeners, we've covered obesity, the heterogeneity of the disease, one size does not fit all.
- 1:49SPEAKER_01: We've talked about phenotypes in order to segment our patient population.
- 1:54SPEAKER_01: And we've also taken a deep dive about amylene biology and physiology.
- 1:59SPEAKER_01: So, Tim, let me start off with some comments I've heard from clinicians.
- 2:03SPEAKER_01: We already have a lot of good medications, GOP1s, GOP, uh uh, GLP1 combinations.
- 2:11SPEAKER_01: Why do we need yet another gut hormone entering the space?
- 2:36SPEAKER_00: You know, it's true these these GLIP 1-based medications that we've had approved since 2021 have really been transformational and given us a level of efficacy we just didn't have before.
- 2:48SPEAKER_00: But you know, what we're looking for right now is a drug that gives us moderate levels of weight loss, approaching 15% uh on on average, generally speaking, that's well tolerated.
- 3:00SPEAKER_00: Whenever you have a GLIP-1 receptor agonist, uh, as a monoagonist or a dual agonist or a triple agonist, that drug is going to activate receptors in the area postrema and is going to cause nausea and other GI symptomatology in many patients, not all patients.
- 3:20SPEAKER_00: Uh, you know, nausea, vomiting, diarrhea, constipation.
- 3:24SPEAKER_00: So we're looking for a medication that really doesn't have those side effects to the same degree, is better tolerated.
- 3:30SPEAKER_00: That's one thing.
- 3:31SPEAKER_00: And as transformational as these medicines are, we still have a problem, Bob, in that many patients stop taking the medicine after one year.
- 3:39SPEAKER_00: And when that happens, there's weight regain, and there's the loss of the benefits of the weight loss, the health benefits.
- 3:47SPEAKER_00: So one reason, it's multifactorial, but one reason patients stop taking the medicines are side effects.
- 3:53SPEAKER_00: Uh, that may be 20% of the patients in some studies.
- 3:57SPEAKER_00: And so, again, we need a medication that can be taken long term, that's well tolerated.
- 4:02SPEAKER_00: And I think the early data indicates that long-acting amylins may fill that bill.
- 4:08SPEAKER_01: Okay, so you see a role for them, which we're going to get into in a little more detail here, particularly which drugs.
- 4:14SPEAKER_01: Tim, the other thing before we get into medications that Dr.
- 4:17SPEAKER_01: Hayes talked a lot about is that the receptor for amylene is not as simple.
- 4:22SPEAKER_01: You know, GLP1 is one receptor.
- 4:23SPEAKER_01: We know what the pathways are.
- 4:25SPEAKER_01: Amylen are different.
- 4:26SPEAKER_01: You got doctor amelins, you know, the uh amylen receptors that combine calcitonin, and then you have the selective amylen receptors.
- 4:34SPEAKER_01: How important do you think it is for clinicians to get into the weeds about which amylen receptor is actually being activated as you start going through these drugs with us?
- 4:46SPEAKER_00: At this stage of the game, I think we just have to look at the clinical trial data that emanates uh from the use of these medications, from the experimental uh uh assessment of these medications.
- 4:58SPEAKER_00: We don't know which is the best way to go here, uh selective amylin agonist versus DACRAs dual that bind both calcitonin and uh amylin receptors.
- 5:10SPEAKER_00: Uh the ones in phase three clinical trials or beginning phase three clinical trials, there's one that's uh selective and two that are DACRAs that bind both receptors.
- 5:21SPEAKER_00: And, you know, they both seem to have efficacy uh and lower side effects.
- 5:26SPEAKER_00: Um, you know, there's some preclinical data indicating that the selective amylins may be more effective for weight loss, but it's we don't know that yet.
- 5:34SPEAKER_00: And I tell you why I like drugs that also bind the calcitonin receptor.
- 5:39SPEAKER_00: You know, I think we we we pay we think about muscle loss that accompanies weight loss, but we also lose bone.
- 5:46SPEAKER_00: You lose 20% of your body weight, you're losing 2 to 3% of your bone mass.
- 5:50SPEAKER_00: And we don't know what the long-term consequences of that may be, uh, particularly in postmenopausal women and elderly individuals, uh, whether that may place patients at increased fracture risk.
- 6:02SPEAKER_00: So um if you're binding the calcitonin receptor, you know, we we used to use, we still use Salmon calcitonin to treat osteoporosis.
- 6:10SPEAKER_00: So there's the possibility it may be uh bone protective.
- 6:15SPEAKER_00: We don't know that yet.
- 6:16SPEAKER_00: It is in preclinical studies, uh, but we we need human data to really see if that's going to preserve bone uh in conjunction with weight loss.
- 6:24SPEAKER_00: But it is a theoretical possibility and advantage.
- 6:28SPEAKER_01: I'm so glad you reiterated the whole idea of preclinical data versus uh translation to clinical trials.
- 6:36SPEAKER_01: And and and Dr.
- 6:37SPEAKER_01: Hayes brought that out a lot, that what we're learning now, we're we're building off of preclinical data, but we don't have the confirmation yet for a lot of these diverse uh effects of AMLIN.
- 6:49SPEAKER_01: Tim, you kind of led the way from clinical, from preclinical to clinical.
- 6:53SPEAKER_01: So can you go over the medications that are currently in development, phase two or phase three, and tell us about those receptors and what we're actually starting to see regarding outcomes with those molecules?
- 7:07SPEAKER_00: Well, I think there are three long-acting amylins, monoagonists, they're kind of leading the charge right now.
- 7:14SPEAKER_00: Uh, they are in phase three trials or entering phase three trials.
- 7:19SPEAKER_00: Uh, we hate we have phase two data uh available.
- 7:23SPEAKER_00: Uh, in one instance, we do have some phase three clinical data.
- 7:26SPEAKER_00: Uh, I would begin with uh cagrolintide.
- 7:30SPEAKER_00: Uh, this is a long-acting amylene.
- 7:32SPEAKER_00: Uh it's been it's been developed as a as a as a dual agonist with semaglitide in the form of CAGRACEMA.
- 7:39SPEAKER_00: Uh, it's it's but we also had uh an arm with just cagrolintide as well in the redefined one trial.
- 7:45SPEAKER_00: So we do have some some monoagonist data there.
- 7:48SPEAKER_00: Uh and it is entering into a phase three clinical trial program to develop it as a monoagonist, and hopefully we'll get approval for that at some point.
- 7:57SPEAKER_00: Uh the second I would mention is uh allora-lintide.
- 8:02SPEAKER_00: Uh this is the one selective uh uh amylin agonist, amylin receptor one, uh, but it's still it binds that 10 times more avidly than calcitonin receptors.
- 8:14SPEAKER_00: So it does have some calcitonin binding activity, but but less so perhaps.
- 8:19SPEAKER_00: Um and uh we do have uh you know very nice, exciting clinical data there, perhaps a little higher level of weight loss than than the others.
- 8:28SPEAKER_00: Uh but you know there's some some caveats there.
- 8:31SPEAKER_00: And then finally, there's petrolintide.
- 8:34SPEAKER_00: Uh these data were phase two data were just presented at the American Diabetes Association meetings in in June of 2026.
- 8:42SPEAKER_00: Uh, and really nice data there.
- 8:45SPEAKER_00: In phase three trials, we have uh cagrintide that I mentioned.
- 8:49SPEAKER_00: Those trials are finished actually, and they've applied for uh FDA for approval.
- 8:54SPEAKER_00: Uh and then xenogamptide is another unimolecular uh peptide that binds both GLIP1 and calcitonin receptors.
- 9:04SPEAKER_00: It's a DACRA uh as well, uh, in terms of its its receptor activation.
- 9:10SPEAKER_00: Uh and those data in phase two trials also look very uh exciting.
- 9:14SPEAKER_00: Uh, and with particularly uh those two drugs, CAGROCEMA and xenogamptide, very nice data in type 2 diabetes uh plus obesity as well.
- 9:24SPEAKER_00: And there's other uh monoagonists in development, some oral long-acting amylins, some uh monthly injectable uh amylins with longer half-life requiring monthly injections as opposed to weekly injections.
- 9:38SPEAKER_00: Uh so it's it's very exciting.
- 9:40SPEAKER_00: There's a there's a huge drive now towards development of long-acting amylins.
- 9:45SPEAKER_01: And Tim, thanks for going over that, Tim.
- 9:47SPEAKER_01: And what kind of weight loss are we seeing?
- 9:49SPEAKER_01: I know the phase two trials are usually shorter than the phase three and so forth, and numbers of participants differ, but what kind of weight loss are are we getting with either the monoagonist or the dual agonist?
- 10:01SPEAKER_01: Because we we want to compare them, not that weight loss is the sole outcome, but to make some comparison to what we currently are using, you know, GLP1 and GLP1 GIP medications.
- 10:28SPEAKER_00: Well, we don't have head-to-head comparisons, so we always have to take this with a grain of salt.
- 10:32SPEAKER_00: I think the monoagonist, uh cagrintide and petrolintide, maybe 11-12% on average.
- 10:40SPEAKER_00: Of course, there's a big variation.
- 10:42SPEAKER_00: Some patients lose more, some patients lose less.
- 10:45SPEAKER_00: Uh allorolintide up to about 20% again, a variation around that mean.
- 10:51SPEAKER_00: Uh with the dual agonists, they're they tend to be more effective.
- 10:54SPEAKER_00: Uh CagroSema, we're seeing, you know, over 20, 22 to 25% weight loss.
- 11:00SPEAKER_00: Uh the senogampti promises to have that much weight loss as well.
- 11:05SPEAKER_00: Uh so uh, you know, they're dual agonists, they're uh uh they're additive uh to the long acting amyla is additive in efficacy to the glip1 receptor agonists.
- 11:16SPEAKER_00: They bind overlapping but different cell types and regions of the brain that do control appetite.
- 11:22SPEAKER_00: So they're they're additive in efficacy.
- 11:24SPEAKER_00: So it's not surprising that the dual agonists have more weight loss efficacy than the monoagonists.
- 11:31SPEAKER_01: So I guess, yeah, and of course, you're a clinical trialist, so uh and pharmaceutical companies looking for monotherapy and then combined therapy.
- 11:39SPEAKER_01: And I guess it's the idea of changing tolerability, getting additive effects, getting diverse uh effects, and so forth.
- 11:47SPEAKER_01: Um, how do you see things emerging in on the clinical realm regarding how clinicians may be thinking about using these meds or what to be looking for with trials coming out?
- 11:59SPEAKER_00: Well, I think uh, you know, we we're we will want to get some of these approved and in the hands of clinicians in real-world practice and see how they perform.
- 12:08SPEAKER_00: So again, we're we're kind of anticipating the future here.
- 12:12SPEAKER_00: Um I I can I can, you know, I think, Bob, as we have more medications available uh to treat this disease, we're going to develop kind of an algorithm algorithmic approaches to care, like we do in hypertension and diabetes.
- 12:28SPEAKER_00: I mean, we'll add a drug that's well tolerated, uh, see how it works, see if we meet our clinical goals, uh, if it doesn't, or even initially or over time, we'll add another medication uh and then have mono uh combination therapy.
- 12:43SPEAKER_00: I think that's what is going to evolve with obesity.
- 12:48SPEAKER_00: And let's think about it this way: if I can just digress for a minute on this.
- 12:52SPEAKER_00: Let's say there's three categories of patients that have obesity.
- 12:56SPEAKER_00: One is the high BMI category.
- 12:59SPEAKER_00: Let's say patients with BMI above 40, above 45, particularly ones that are having mobility issues and difficulty getting around.
- 13:08SPEAKER_00: There, we're going to want our dual and triple agonists.
- 13:11SPEAKER_00: We want to get a significant substantial weight loss off of these individuals, improve their quality of life.
- 13:17SPEAKER_00: Some of them may be candidates for bariatric surgery.
- 13:21SPEAKER_00: Another category of patients that have obesity will have complications that have been shown to be effectively treated by GLIP 1-based medications in phase three clinical trials where it's the improvement in the complications that's the primary outcome measure, not weight loss per se.
- 13:41SPEAKER_00: And I think in those patients will want to practice evidence-based medicine, we will want to use a GLIP-1-based medication that's been shown to effectively ameliorate that specific complication in our patient.
- 13:54SPEAKER_00: Those complications could include secondary prevention of cardiovascular disease events, could involve uh treatment of MASH, could involve treatment of obstructive sleep apnea.
- 14:07SPEAKER_00: Uh, these medications are really effective in type 2 diabetes.
- 14:11SPEAKER_00: But you know, if you look at all of the patients that have obesity, and this is the third category of patients, most of them do not have these complications that uh have been shown to be effectively treated by glyp 1-based medicines.
- 14:23SPEAKER_00: And in those patients, I think a long acting medicine like a long-acting amount would be a perfectly reasonable, evidence-based, first-line drug to use.
- 14:33SPEAKER_00: Okay, start a medication that's well tolerated, get the patient losing some weight, see what the health benefits are, see if you're a target.
- 14:42SPEAKER_00: Many patients will be a target with weight loss that approaches 15%.
- 14:47SPEAKER_00: And I think patients will do very well.
- 14:49SPEAKER_00: I think primary care will have an easier time with a well-tolerated medication.
- 14:54SPEAKER_00: If you don't reach your clinical goals, then add a GLIP 1 uh to the amylen or use a combination drug that has both agonisms.
- 15:02SPEAKER_00: Uh so I just if you I'm just hypothesizing that that is a future algorithm and rational approach to care that could emerge uh from these trials.
- 15:14SPEAKER_01: Yeah, I think your separation out or the phenotyping or looking at the heterogeneity of patient population and response, I think it's right on target.
- 15:23SPEAKER_01: And I think that's exactly what the clinician is going to be looking for.
- 15:26SPEAKER_01: You know, tolerability is important.
- 15:28SPEAKER_01: You you talked about different types and so on, but tolerability is.
- 15:32SPEAKER_01: This drug, uh, amylin works mostly in the brainstem or, you know, the area post-trema, which is kind of where Dr.
- 15:38SPEAKER_01: Hayes was pointing out is an is it where nausea is typically um triggered.
- 15:42SPEAKER_01: And I'm wondering if you have any thoughts, because the petrolinti data and some others have better tolerability, which is kind of opposite, I think, of what we're hearing regarding some of the biology.
- 15:52SPEAKER_01: Do you have any thoughts about preclinical versus clinical uh observations at that point?
- 15:59SPEAKER_00: Well, I think we could go a long way with the clinical data we have.
- 16:03SPEAKER_00: You know, I mean, these, well, we know preclinically these drugs do go to regions of the brain that control appetite, the hypothalamus and the brainstem, as you mentioned.
- 16:13SPEAKER_00: Uh they bind some cells in common with GLIP 1, but they bind some cells separately from glip 1.
- 16:21SPEAKER_00: They're uniquely activated by amylin agonists.
- 16:25SPEAKER_00: Uh, and I think that could explain less of the nausea and GI symptomatology.
- 16:30SPEAKER_00: Uh, they're going to the haria postrema, but they're binding different cell types.
- 16:35SPEAKER_00: And I'm just hypothesizing that's what's responsible for better tolerability in combination with the decrease in appetite.
- 16:44SPEAKER_00: We know from uh the petrolitine and cagrolintide, no drugs perfect.
- 16:49SPEAKER_00: There is some nausea, but the rates of nausea are about half of those that which is observed with the GLIP-1-based drugs in phase three clinical trials.
- 16:58SPEAKER_00: And rates of nausea, vomiting, uh, and diarrhea rates of vomiting, diarrhea, constipation approach that of placebo.
- 17:07SPEAKER_00: Uh, so half the rates of nausea and rates of constipation, vomiting, diarrhea equal to placebo.
- 17:15SPEAKER_00: Very good data on vomiting, very low rates of vomiting, and low rates of drug discontinuation due to uh side effects.
- 17:24SPEAKER_00: Allora lintide uh is uh has a little bit higher rates of symptomatology.
- 17:30SPEAKER_00: Uh the nausea rates there do approach uh glyp one-based medications, um, and uh some of the rates of but the nausea, vomiting, diarrhea a little less, uh, but uh and also higher rates of fatigue were noticed in that study.
- 17:44SPEAKER_00: But that was a study where the dose was pushed towards the maximal dose kind of relentlessly.
- 17:50SPEAKER_00: There was a big emphasis on that, like obtaining maximal dose according to protocol, according to schedule.
- 17:58SPEAKER_00: And when you do that, you're gonna elicit more GI symptomatology.
- 18:02SPEAKER_00: So your the study design, I think, sacrificed efficacy for tolerability.
- 18:08SPEAKER_00: And I think once if it gets in the clinician's hands, we can deal with that.
- 18:11SPEAKER_00: We can we can advance that medication slowly and take advantage of a potential uh less uh improvement in tolerability.
- 18:18SPEAKER_00: We'll have to see.
- 18:20SPEAKER_01: Tim, the medications currently on the market, you know, GLP1 receptor agonists as well as the GLP1 GIP dual receptor agonist, have cardiometabolic outcomes really as part of their trials.
- 18:31SPEAKER_01: Would you expect different outcomes if you're looking at an amylin receptor agonist?
- 18:37SPEAKER_00: Well, you know, we don't have cardiovascular outcome trial data yet with the long-acting amylins.
- 18:43SPEAKER_00: Uh, we do know uh that the pulse rate decreases by uh three or four beats per minute, as opposed to increasing three or four beats per minute.
- 18:53SPEAKER_00: That's uh we see with CLIP 1-based medications.
- 18:57SPEAKER_00: Uh, we know that blood pressure goes down when these amylins are used as single agents.
- 19:03SPEAKER_00: Uh we know that the CRP, we know that the CRP also declines uh and uh lipids improve, and glycemia improves together with a decrease in fasting insulin, indicative of an increase in insulin sensitivity.
- 19:20SPEAKER_00: So all of these point uh to in a good direction in terms of cardiovascular safety.
- 19:26SPEAKER_00: But again, we'll have to have to get these trials done.
- 19:30SPEAKER_01: Well, Tim, I think you did an excellent job talking about medications that are not available yet, but I hope prepare uh all the attendees or listeners to what to be looking for and options of how to think about using these medications in clinical practice as we see them approved and increase the options in our toolbox.
- 19:51SPEAKER_01: Before we come to a close, I wonder if you have some closing thoughts yourself about how clinicians should be thinking about the next, you know, two to five years when we start seeing more amylin-based medications coming out.
- 20:06SPEAKER_00: Well, we'll have more tools in our arrows in our quiver, if you will.
- 20:10SPEAKER_00: And we know that as effective as these patients may be in clinical trials, there's always some patients that don't respond adequately.
- 20:18SPEAKER_00: Uh, and we need to have substitute medications to try to reach our clinical goals.
- 20:23SPEAKER_00: So the more medications out there, the better.
- 20:26SPEAKER_00: That's one thing.
- 20:27SPEAKER_00: Uh, when we add amylin to a glip one, we don't really add to the side effect burden of the drug over and above the glyp one component.
- 20:38SPEAKER_00: Uh so it is a therapeutic option, a dual agonist where we get more efficacy without sacrificing uh uh tolerability.
- 20:46SPEAKER_00: Uh and it'd be another option.
- 20:48SPEAKER_00: I mean, glip one's being combined with GIP and glucagon.
- 20:52SPEAKER_00: Well, uh, this is just another option that might be beneficial in some patients.
- 20:57SPEAKER_00: And if the preclinical data are shown to apply to human physiology with respect to bone loss, with respect to preservation of muscle at the expense of fat, which is a preclinical observation, uh, also keeping up on the uh uh resting energy expenditure that usually declines with weight loss, but in preclinical data, weight loss with long-acting amelins, you preserve that that resting energy expenditure, which will help maintain weight loss.
- 21:27SPEAKER_00: So there's if we're waiting to see whether those translate into human uh uh uh physiology.
- 21:34SPEAKER_00: And again, you know, we have to find ways to keep patients on these medications over, in essence, a lifetime of uh, and we're we're not doing very well with that.
- 21:45SPEAKER_00: And so we're gonna have to use these medications, uh, particularly maybe long-acting amlins with that require less frequent injections, monthly injections or oral amylins, if patients prefer oral medications.
- 21:59SPEAKER_00: Um, so we'll have those choices to experiment with.
- 22:03SPEAKER_00: Negotiating care with our patients, getting feedback from our patients.
- 22:06SPEAKER_00: We have to meet the patients where they are.
- 22:09SPEAKER_00: And that's the only way we're going to keep patients on these medications long term, because again, uh it's multifactorial why they may want to stop them.
- 22:19SPEAKER_01: Tim, great summary on why we need more arrows in our quiver, as you said, or or tools in our toolbox.
- 22:27SPEAKER_01: You said that really wonderfully.
- 22:29SPEAKER_01: Well, it's time to wrap up our conversation and indeed the CME snack series.
- 22:34SPEAKER_01: Thank you very much, Tim, for sharing your expertise.
- 22:36SPEAKER_01: It's always a pleasure chatting with you.
- 22:38SPEAKER_01: As you know, we've done this for years and years.
- 22:41SPEAKER_01: And thank you, our audience, for participating.
- 22:43SPEAKER_01: We hope the information presented in the series will be helpful to you and in your practice.
- 22:48SPEAKER_01: To receive CMEC credit, please complete the post test evaluation.
- 22:54SPEAKER_01: And if you've missed any of the previous snacks in the series, they're listed on your screen now and available at cmeoutfitters.com.
- 23:03SPEAKER_01: Thank you.